|Bid||64.99 x 800|
|Ask||65.78 x 800|
|Day's range||63.64 - 66.80|
|52-week range||60.57 - 232.76|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||119.33|
Shares of Novocure Limited (NASDAQ: NVCR) are jumping 12.9% higher as of 11:09 a.m. ET on Thursday. The solid gain came after investment firm Truist Financial upgraded the stock from a hold to a buy recommendation. Truist kept its 12-month price target for the stock at $125, which represents upside potential of more than 70%.
ST. HELIER, Jersey, January 10, 2022--Novocure today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2021.
Healthcare can be a wonderful industry for investors. Telemedicine has been a big theme during COVID, especially during the height of lockdowns when patients were either frightened or at risk of infection, choosing instead to connect with healthcare providers digitally. Teladoc Health (NYSE: TDOC) has played a significant role in meeting this need and has grown rapidly as a result.